Emodin Isolated from Polygoni cuspidati Radix Inhibits TNF-α and IL-6 Release by Blockading NF-κB and MAP Kinase Pathways in Mast Cells Stimulated with PMA Plus A23187
Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several beneficial pharmacologic effects, which include anti-cancer, anti-diabetic, and anti-inflammatory activities. In this study, the authors examined the effect of emodin on the production of proin...
Saved in:
| Published in | Biomolecules & therapeutics Vol. 21; no. 6; pp. 435 - 441 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Society of Applied Pharmacology
01.11.2013
한국응용약물학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1976-9148 2005-4483 |
| DOI | 10.4062/biomolther.2013.068 |
Cover
| Abstract | Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several beneficial pharmacologic effects, which include anti-cancer, anti-diabetic, and anti-inflammatory activities. In this study, the authors examined the effect of emodin on the production of proinflammatory cytokines, such as, tumor necrosis factor (TNF)-α and interleukin (IL)-6, in mouse bone marrow-derived mast cells (BMMCs) stimulated with phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187. To investigate the mechanism responsible for the regulation of pro-inflammatory cytokine production by emodin, the authors assessed its effects on the activations of transcriptional factor nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs). Emodin attenuated the nuclear translocation of (NF)-κB p65 and its DNA-binding activity by reducing the phosphorylation and degradation of IκBα and the phosphorylation of IκB kinase B (IKK). Furthermore, emodin dose-dependently attenuated the phosphorylations of MAPKs, such as, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAP kinase, and the stress-activated protein kinases (SAPK)/c-Jun-N-terminal kinase (JNK). Taken together, the findings of this study suggest that the anti-inflammatory effects of emodin on PMA plus A23187-stimulated BMMCs are mediated via the inhibition of NF-κB activation and of the MAPK pathway. |
|---|---|
| AbstractList | Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several beneficial pharmacologic effects, which include anti-cancer, anti-diabetic, and anti-inflammatory activities. In this study, the authors examined the effect of emodin on the production of proinflammatory cytokines, such as, tumor necrosis factor (TNF)-α and interleukin (IL)-6, in mouse bone marrow-derived mast cells (BMMCs) stimulated with phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187. To investigate the mechanism responsible for the regulation of pro-inflammatory cytokine production by emodin, the authors assessed its effects on the activations of transcriptional factor nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs). Emodin attenuated the nuclear translocation of (NF)-κB p65 and its DNA-binding activity by reducing the phosphorylation and degradation of IκBα and the phosphorylation of IκB kinase B (IKK). Furthermore, emodin dose-dependently attenuated the phosphorylations of MAPKs, such as, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAP kinase, and the stress-activated protein kinases (SAPK)/c-Jun-N-terminal kinase (JNK). Taken together, the findings of this study suggest that the anti-inflammatory effects of emodin on PMA plus A23187-stimulated BMMCs are mediated via the inhibition of NF-κB activation and of the MAPK pathway. Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several benefi cial pharmacologic effects, which include anti-cancer, anti-diabetic, and anti-infl ammatory activities. In this study, the authors examined the effect of emodin on the production of proinfl ammatory cytokines, such as, tumor necrosis factor (TNF)-α and interleukin (IL)-6, in mouse bone marrow-derived mast cells (BMMCs) stimulated with phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187. To investigate the mechanism responsible for the regulation of pro-infl ammatory cytokine production by emodin,the authors assessed its effects on the activations of transcriptional factor nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs). Emodin attenuated the nuclear translocation of (NF)-κB p65 and its DNA-binding activity by reducing the phosphorylation and degradation of IκBα and the phosphorylation of IκB kinase B (IKK). Furthermore, emodin dose-dependently attenuated the phosphorylations of MAPKs, such as, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAP kinase, and the stress-activated protein kinases (SAPK)/c-Jun-N-terminal kinase (JNK). Taken together, the fi ndings of this study suggest that the anti-infl ammatory effects of emodin on PMA plus A23187-stimulated BMMCs are mediated via the inhibition of NF-κB activation and of the MAPK pathway. KCI Citation Count: 27 Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several beneficial pharmacologic effects, which include anti-cancer, anti-diabetic, and anti-inflammatory activities. In this study, the authors examined the effect of emodin on the production of proinflammatory cytokines, such as, tumor necrosis factor (TNF)-α and interleukin (IL)-6, in mouse bone marrow-derived mast cells (BMMCs) stimulated with phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187. To investigate the mechanism responsible for the regulation of pro-inflammatory cytokine production by emodin, the authors assessed its effects on the activations of transcriptional factor nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs). Emodin attenuated the nuclear translocation of (NF)-κB p65 and its DNA-binding activity by reducing the phosphorylation and degradation of IκBα and the phosphorylation of IκB kinase B (IKK). Furthermore, emodin dose-dependently attenuated the phosphorylations of MAPKs, such as, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAP kinase, and the stress-activated protein kinases (SAPK)/c-Jun-N-terminal kinase (JNK). Taken together, the findings of this study suggest that the anti-inflammatory effects of emodin on PMA plus A23187-stimulated BMMCs are mediated via the inhibition of NF-κB activation and of the MAPK pathway. Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several beneficial pharmacologic effects, which include anti-cancer, anti-diabetic, and anti-inflammatory activities. In this study, the authors examined the effect of emodin on the production of proinflammatory cytokines, such as, tumor necrosis factor (TNF)-α and interleukin (IL)-6, in mouse bone marrow-derived mast cells (BMMCs) stimulated with phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187. To investigate the mechanism responsible for the regulation of pro-inflammatory cytokine production by emodin, the authors assessed its effects on the activations of transcriptional factor nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs). Emodin attenuated the nuclear translocation of (NF)-κB p65 and its DNA-binding activity by reducing the phosphorylation and degradation of IκBα and the phosphorylation of IκB kinase B (IKK). Furthermore, emodin dose-dependently attenuated the phosphorylations of MAPKs, such as, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAP kinase, and the stress-activated protein kinases (SAPK)/c-Jun-N-terminal kinase (JNK). Taken together, the findings of this study suggest that the anti-inflammatory effects of emodin on PMA plus A23187-stimulated BMMCs are mediated via the inhibition of NF-κB activation and of the MAPK pathway.Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several beneficial pharmacologic effects, which include anti-cancer, anti-diabetic, and anti-inflammatory activities. In this study, the authors examined the effect of emodin on the production of proinflammatory cytokines, such as, tumor necrosis factor (TNF)-α and interleukin (IL)-6, in mouse bone marrow-derived mast cells (BMMCs) stimulated with phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187. To investigate the mechanism responsible for the regulation of pro-inflammatory cytokine production by emodin, the authors assessed its effects on the activations of transcriptional factor nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs). Emodin attenuated the nuclear translocation of (NF)-κB p65 and its DNA-binding activity by reducing the phosphorylation and degradation of IκBα and the phosphorylation of IκB kinase B (IKK). Furthermore, emodin dose-dependently attenuated the phosphorylations of MAPKs, such as, extracellular signal-regulated kinase 1/2 (ERK1/2), p38 MAP kinase, and the stress-activated protein kinases (SAPK)/c-Jun-N-terminal kinase (JNK). Taken together, the findings of this study suggest that the anti-inflammatory effects of emodin on PMA plus A23187-stimulated BMMCs are mediated via the inhibition of NF-κB activation and of the MAPK pathway. |
| Author | Lu, Yue Kim, Mi Jin Son, Jong Keun Li, Xian Park, Pil-Hoon Hwang, Seung-Lark Jeong, Yong-Tae Chang, Hyeun Wook |
| AuthorAffiliation | 1 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China, College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Republic of Korea 2 College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Republic of Korea |
| AuthorAffiliation_xml | – name: 2 College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Republic of Korea – name: 1 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China, College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Republic of Korea |
| Author_xml | – sequence: 1 givenname: Yue surname: Lu fullname: Lu, Yue – sequence: 2 givenname: Yong-Tae surname: Jeong fullname: Jeong, Yong-Tae – sequence: 3 givenname: Xian surname: Li fullname: Li, Xian – sequence: 4 givenname: Mi Jin surname: Kim fullname: Kim, Mi Jin – sequence: 5 givenname: Pil-Hoon surname: Park fullname: Park, Pil-Hoon – sequence: 6 givenname: Seung-Lark surname: Hwang fullname: Hwang, Seung-Lark – sequence: 7 givenname: Jong Keun surname: Son fullname: Son, Jong Keun – sequence: 8 givenname: Hyeun Wook surname: Chang fullname: Chang, Hyeun Wook |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24404333$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001822693$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9ksGOEyEcxolZ43ZXn8DEcPQyFYbpDFxMus2uNrba1HomDDAtloE6MK59JI9efQifSdq6rnrw9A_h9_0_wvddgDPnnQbgKUbDApX5i9r41tu40d0wR5gMUUkfgEGO0CgrCkrOwACzqswYLug5uAjhI0JlhUflI3CeFwUqCCED8PW69co4OA3eiqgVbDrfwoW3-7V3Bso-7IwS0cClUOYLnLqNqU0McPX2JvvxDQqn4HSWlXCprRZBw3oPr6yX20S7NTxA36-O1Hy8gG-MOzALETe3Yh9g8p2LEOFEWxvg-2ja_vSIWxM3cDEfw4XtAxznBNPqMXjYCBv0k1_zEny4uV5NXmezd6-mk_EskwWhMcvVSMuqQUqpPEeslrKodS5wzTSjFSnrCqUTpURI3DDRoKqqKaVSi3qkkJbkEjw_7XVdw7fScC_Mca4933Z8vFxNOWaMEprQlyd019etVlK72AnLd51pRbc_Cv--cWaT1nzmhFYs5XLvtev8p16HyFsTZPoN4bTvA8cFQxUijIwS-uxPr98md1EmgJ0A2fkQOt1waWJKzh-sjeUY8UNt-H1t-KE2PNUmack_2rv1_1P9BCZdzCo |
| CitedBy_id | crossref_primary_10_3390_md17040244 crossref_primary_10_1002_bkcs_10411 crossref_primary_10_1016_j_mtadv_2023_100341 crossref_primary_10_1021_np500296b crossref_primary_10_1177_1933719116645192 crossref_primary_10_3892_ijmm_2014_2032 crossref_primary_10_1007_s10068_016_0260_y crossref_primary_10_3389_fphar_2016_00448 crossref_primary_10_3389_fphar_2021_687970 crossref_primary_10_3389_fphar_2023_1240820 crossref_primary_10_1007_s11255_020_02739_w crossref_primary_10_1016_j_intimp_2016_06_018 crossref_primary_10_1016_j_biopha_2023_114539 crossref_primary_10_3390_pharmaceutics13111916 crossref_primary_10_1016_j_foodchem_2021_130569 crossref_primary_10_3892_mmr_2015_4214 crossref_primary_10_1016_j_anireprosci_2014_09_002 crossref_primary_10_1016_j_biopha_2021_112181 crossref_primary_10_12688_f1000research_22624_1 crossref_primary_10_1590_1519_6984_243775 crossref_primary_10_1016_j_biomaterials_2019_119491 crossref_primary_10_1186_1472_6882_14_477 crossref_primary_10_1016_S1875_5364_16_30042_5 crossref_primary_10_3390_molecules22101754 crossref_primary_10_7732_kjpr_2015_28_3_321 crossref_primary_10_1016_j_sajb_2023_01_013 crossref_primary_10_1016_j_intimp_2020_107020 crossref_primary_10_1177_1534735420972486 |
| Cites_doi | 10.1152/ajpregu.00376.2010 10.3109/1547691X.2012.700652 10.1159/000107285 10.1189/jlb.0204115 10.1111/j.1745-7254.2006.00264.x 10.1016/j.bcp.2011.08.022 10.1111/j.1476-5381.2010.00993.x 10.1007/s12272-012-0909-x 10.3109/13880201003770150 10.1016/j.bbamcr.2003.09.003 10.1189/jlb.1003498 10.1152/physrev.1997.77.4.1033 10.1002/j.1460-2075.1996.tb00542.x 10.1016/j.immuni.2009.08.014 10.1074/jbc.R110.197046 10.1084/jem.185.1.43 10.1038/nri2327 10.1016/j.bmcl.2011.11.008 10.1016/S0021-9258(17)31786-6 10.1111/j.1476-5381.2010.00826.x 10.4049/jimmunol.162.9.5367 10.1002/jcb.21805 10.1146/annurev.immunol.21.120601.141025 10.3181/0705-RM-118 10.1074/jbc.M212389200 10.1016/j.fct.2012.03.076 10.1093/rheumatology/ket178 10.1074/jbc.M112.441477 10.1016/j.jaci.2012.07.014 10.1073/pnas.0501912102 10.3390/ijms13022276 10.1186/1476-9255-6-1 10.1016/S1044-579X(02)00096-2 10.1055/s-0031-1298626 10.1016/j.fct.2011.11.046 10.1016/S1734-1140(12)70917-9 10.1074/jbc.M300847200 10.1111/j.1440-1681.2010.05378.x 10.1007/BF02976693 10.1016/S0898-6568(00)00149-2 10.1038/sj.onc.1208656 10.1016/S0006-291X(03)01073-8 10.1016/S0091-6749(97)70089-7 10.1002/jcb.24232 10.1126/science.1062677 10.1002/jcb.10729 10.1248/bpb.b13-00146 10.1073/pnas.94.12.6358 10.1101/gad.1228704 |
| ContentType | Journal Article |
| Copyright | Copyright ©2013, The Korean Society of Applied Pharmacology 2013 |
| Copyright_xml | – notice: Copyright ©2013, The Korean Society of Applied Pharmacology 2013 |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.4062/biomolther.2013.068 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2005-4483 |
| EndPage | 441 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_199838 PMC3879914 24404333 10_4062_biomolther_2013_068 |
| Genre | Journal Article |
| GroupedDBID | --- 23N 5-W 5GY 8JR 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. F5P HYE HZB JDI KQ8 M48 OK1 PGMZT RPM NPM 7X8 5PM .UV ACYCR |
| ID | FETCH-LOGICAL-c438t-2d5ec7f0ddd2209bcc4be2a1b9e98736b702a1883ac1f9af077b888ceab5d0ec3 |
| IEDL.DBID | M48 |
| ISSN | 1976-9148 |
| IngestDate | Tue Nov 21 21:39:56 EST 2023 Thu Aug 21 18:42:41 EDT 2025 Thu Jul 10 18:38:42 EDT 2025 Thu Apr 03 06:57:53 EDT 2025 Thu Apr 24 23:05:13 EDT 2025 Tue Jul 01 04:15:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Emodin Mitogen-activated protein kinase NF-κB Pro-inflammatory cytokine PMA plus A23187 Bone marrow-derived mast cells |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c438t-2d5ec7f0ddd2209bcc4be2a1b9e98736b702a1883ac1f9af077b888ceab5d0ec3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 G704-000363.2013.21.6.003 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2013.068 |
| PMID | 24404333 |
| PQID | 1490703935 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_199838 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3879914 proquest_miscellaneous_1490703935 pubmed_primary_24404333 crossref_citationtrail_10_4062_biomolther_2013_068 crossref_primary_10_4062_biomolther_2013_068 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20131101 |
| PublicationDateYYYYMMDD | 2013-11-01 |
| PublicationDate_xml | – month: 11 year: 2013 text: 20131101 day: 1 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Biomolecules & therapeutics |
| PublicationTitleAlternate | Biomol Ther (Seoul) |
| PublicationYear | 2013 |
| Publisher | The Korean Society of Applied Pharmacology 한국응용약물학회 |
| Publisher_xml | – name: The Korean Society of Applied Pharmacology – name: 한국응용약물학회 |
| References | (OOOMB4_2013_v21n6_435_026) 2006; 27 (OOOMB4_2013_v21n6_435_012) 2008; 8 (OOOMB4_2013_v21n6_435_030) 2012; 50 (OOOMB4_2013_v21n6_435_004) 1999; 162 (OOOMB4_2013_v21n6_435_049) 2005; 24 (OOOMB4_2013_v21n6_435_018) 2004; 18 (OOOMB4_2013_v21n6_435_014) 2013; 10 (OOOMB4_2013_v21n6_435_028) 2010; 37 (OOOMB4_2013_v21n6_435_038) 2005; 77 (OOOMB4_2013_v21n6_435_047) 2012; 78 (OOOMB4_2013_v21n6_435_016) 2003; 278 (OOOMB4_2013_v21n6_435_032) 2010; 161 (OOOMB4_2013_v21n6_435_019) 2008; 105 (OOOMB4_2013_v21n6_435_010) 1997; 99 (OOOMB4_2013_v21n6_435_035) 2011; 286 (OOOMB4_2013_v21n6_435_036) 1994; 269 (OOOMB4_2013_v21n6_435_042) 2011; 300 (OOOMB4_2013_v21n6_435_043) 2013; 288 (OOOMB4_2013_v21n6_435_001) 2012; 13 (OOOMB4_2013_v21n6_435_024) 2003; 26 (OOOMB4_2013_v21n6_435_044) 2004; 91 (OOOMB4_2013_v21n6_435_037) 2005; 102 (OOOMB4_2013_v21n6_435_039) 2013; 131 (OOOMB4_2013_v21n6_435_025) 2010; 48 (OOOMB4_2013_v21n6_435_031) 2011; 82 (OOOMB4_2013_v21n6_435_003) 2003; 1643 (OOOMB4_2013_v21n6_435_040) 2009; 6 (OOOMB4_2013_v21n6_435_023) 2003; 306 (OOOMB4_2013_v21n6_435_046) 1997; 185 (OOOMB4_2013_v21n6_435_013) 2005; 23 (OOOMB4_2013_v21n6_435_017) 2012; 22 (OOOMB4_2013_v21n6_435_007) 2004; 76 (OOOMB4_2013_v21n6_435_005) 2009; 31 (OOOMB4_2013_v21n6_435_011) 2010; 161 (OOOMB4_2013_v21n6_435_008) 2012; 113 (OOOMB4_2013_v21n6_435_022) 1997; 94 (OOOMB4_2013_v21n6_435_009) 2012; 50 (OOOMB4_2013_v21n6_435_048) 2012; 64 (OOOMB4_2013_v21n6_435_002) 2003; 13 (OOOMB4_2013_v21n6_435_029) 2013; 36 (OOOMB4_2013_v21n6_435_045) 2003; 278 (OOOMB4_2013_v21n6_435_034) 2007; 14 (OOOMB4_2013_v21n6_435_041) 2001; 293 (OOOMB4_2013_v21n6_435_021) 2013; 52 (OOOMB4_2013_v21n6_435_033) 1997; 77 (OOOMB4_2013_v21n6_435_015) 2001; 13 (OOOMB4_2013_v21n6_435_027) 2007; 232 (OOOMB4_2013_v21n6_435_006) 1996; 15 (OOOMB4_2013_v21n6_435_020) 2012; 35 9177222 - Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6358-63 12637577 - J Biol Chem. 2003 Jun 20;278(25):22237-42 14654230 - Biochim Biophys Acta. 2003 Dec 7;1643(1-3):75-83 15784689 - J Leukoc Biol. 2005 Jun;77(6):975-83 18040066 - Exp Biol Med (Maywood). 2007 Dec;232(11):1425-31 8071353 - J Biol Chem. 1994 Sep 2;269(35):22269-75 12507553 - Semin Cancer Biol. 2003 Feb;13(1):15-28 22137788 - Bioorg Med Chem Lett. 2012 Jan 1;22(1):323-6 8617238 - EMBO J. 1996 Apr 15;15(8):1914-23 20726986 - Br J Pharmacol. 2010 Dec;161(7):1628-44 23054715 - Arch Pharm Res. 2012 Sep;35(9):1583-9 8996240 - J Exp Med. 1997 Jan 6;185(1):43-53 19766085 - Immunity. 2009 Sep 18;31(3):425-37 20925591 - Pharm Biol. 2010 Nov;48(11):1285-90 22673833 - Planta Med. 2012 Jun;78(10):943-50 22484343 - Food Chem Toxicol. 2012 Jul;50(7):2368-75 21907188 - Biochem Pharmacol. 2011 Dec 1;82(11):1700-8 15371334 - Genes Dev. 2004 Sep 15;18(18):2195-224 22830990 - J Immunotoxicol. 2013 Apr-Jun;10 (2):133-40 15856023 - Oncogene. 2005 Jun 30;24(28):4486-95 9042038 - J Allergy Clin Immunol. 1997 Feb;99(2):155-60 22730200 - J Cell Biochem. 2012 Nov;113(11):3547-58 11257452 - Cell Signal. 2001 Feb;13(2):85-94 18483499 - Nat Rev Immunol. 2008 Jun;8(6):478-86 19133134 - J Inflamm (Lond). 2009 Jan 08;6:1 18494000 - J Cell Biochem. 2008 Sep 1;105(1):70-80 22939756 - J Allergy Clin Immunol. 2013 Feb;131(2):501-11.e1 23719635 - Biol Pharm Bull. 2013;36(8):1370-4 21325641 - Am J Physiol Regul Integr Comp Physiol. 2011 May;300(5):R1152-62 11520989 - Science. 2001 Aug 24;293(5534):1495-9 12711606 - J Biol Chem. 2003 Jun 27;278(26):24233-41 20337656 - Clin Exp Pharmacol Physiol. 2010 Aug;37(8):790-4 10228013 - J Immunol. 1999 May 1;162(9):5367-73 22408453 - Int J Mol Sci. 2012;13(2):2276-89 9354811 - Physiol Rev. 1997 Oct;77(4):1033-79 12821113 - Biochem Biophys Res Commun. 2003 Jul 11;306(4):805-11 12785732 - Arch Pharm Res. 2003 May;26(5):367-74 15840716 - Proc Natl Acad Sci U S A. 2005 May 3;102(18):6467-72 23238477 - Pharmacol Rep. 2012;64(5):1216-22 14689584 - J Cell Biochem. 2004 Jan 1;91(1):100-17 21799018 - J Biol Chem. 2011 Sep 23;286(38):32883-9 22154852 - Food Chem Toxicol. 2012 Mar;50(3-4):913-9 20718744 - Br J Pharmacol. 2010 Sep;161(1):113-26 17700037 - Neuroimmunomodulation. 2007;14(1):24-31 23303186 - J Biol Chem. 2013 Feb 22;288(8):5732-42 15316034 - J Leukoc Biol. 2004 Nov;76(5):1075-81 15771585 - Annu Rev Immunol. 2005;23:749-86 16490171 - Acta Pharmacol Sin. 2006 Mar;27(3):339-46 23685361 - Rheumatology (Oxford). 2013 Sep;52(9):1583-91 |
| References_xml | – volume: 300 start-page: R1152 year: 2011 ident: OOOMB4_2013_v21n6_435_042 publication-title: Am. J. Physiol. Regul. Integr. Comp. Physiol. doi: 10.1152/ajpregu.00376.2010 – volume: 10 start-page: 133 year: 2013 ident: OOOMB4_2013_v21n6_435_014 publication-title: J. Immunotoxicol. doi: 10.3109/1547691X.2012.700652 – volume: 14 start-page: 24 year: 2007 ident: OOOMB4_2013_v21n6_435_034 publication-title: Neuroimmunomodulation doi: 10.1159/000107285 – volume: 77 start-page: 975 year: 2005 ident: OOOMB4_2013_v21n6_435_038 publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.0204115 – volume: 27 start-page: 339 year: 2006 ident: OOOMB4_2013_v21n6_435_026 publication-title: Acta Pharmacol. Sin. doi: 10.1111/j.1745-7254.2006.00264.x – volume: 82 start-page: 1700 year: 2011 ident: OOOMB4_2013_v21n6_435_031 publication-title: Biochem. Pharmacol doi: 10.1016/j.bcp.2011.08.022 – volume: 161 start-page: 1628 year: 2010 ident: OOOMB4_2013_v21n6_435_032 publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2010.00993.x – volume: 35 start-page: 1583 year: 2012 ident: OOOMB4_2013_v21n6_435_020 publication-title: Arch. Pharm. Res. doi: 10.1007/s12272-012-0909-x – volume: 48 start-page: 1285 year: 2010 ident: OOOMB4_2013_v21n6_435_025 publication-title: Pharm. Biol. doi: 10.3109/13880201003770150 – volume: 1643 start-page: 75 year: 2003 ident: OOOMB4_2013_v21n6_435_003 publication-title: Biochim. Biophys. Acta doi: 10.1016/j.bbamcr.2003.09.003 – volume: 76 start-page: 1075 year: 2004 ident: OOOMB4_2013_v21n6_435_007 publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.1003498 – volume: 77 start-page: 1033 year: 1997 ident: OOOMB4_2013_v21n6_435_033 publication-title: Physiol. Rev. doi: 10.1152/physrev.1997.77.4.1033 – volume: 15 start-page: 1914 year: 1996 ident: OOOMB4_2013_v21n6_435_006 publication-title: EMBO J. doi: 10.1002/j.1460-2075.1996.tb00542.x – volume: 31 start-page: 425 year: 2009 ident: OOOMB4_2013_v21n6_435_005 publication-title: Immunity doi: 10.1016/j.immuni.2009.08.014 – volume: 286 start-page: 32883 year: 2011 ident: OOOMB4_2013_v21n6_435_035 publication-title: J. Biol. Chem. doi: 10.1074/jbc.R110.197046 – volume: 185 start-page: 43 year: 1997 ident: OOOMB4_2013_v21n6_435_046 publication-title: J. Exp. Med. doi: 10.1084/jem.185.1.43 – volume: 8 start-page: 478 year: 2008 ident: OOOMB4_2013_v21n6_435_012 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri2327 – volume: 22 start-page: 323 year: 2012 ident: OOOMB4_2013_v21n6_435_017 publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2011.11.008 – volume: 269 start-page: 22269 year: 1994 ident: OOOMB4_2013_v21n6_435_036 publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(17)31786-6 – volume: 161 start-page: 113 year: 2010 ident: OOOMB4_2013_v21n6_435_011 publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2010.00826.x – volume: 162 start-page: 5367 year: 1999 ident: OOOMB4_2013_v21n6_435_004 publication-title: J. Immunol. doi: 10.4049/jimmunol.162.9.5367 – volume: 105 start-page: 70 year: 2008 ident: OOOMB4_2013_v21n6_435_019 publication-title: J. Cell. Biochem. doi: 10.1002/jcb.21805 – volume: 23 start-page: 749 year: 2005 ident: OOOMB4_2013_v21n6_435_013 publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.21.120601.141025 – volume: 232 start-page: 1425 year: 2007 ident: OOOMB4_2013_v21n6_435_027 publication-title: Exp. Biol. Med. (Maywood) doi: 10.3181/0705-RM-118 – volume: 278 start-page: 24233 year: 2003 ident: OOOMB4_2013_v21n6_435_045 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M212389200 – volume: 50 start-page: 2368 year: 2012 ident: OOOMB4_2013_v21n6_435_009 publication-title: Food Chem. Toxicol. doi: 10.1016/j.fct.2012.03.076 – volume: 52 start-page: 1583 year: 2013 ident: OOOMB4_2013_v21n6_435_021 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/ket178 – volume: 288 start-page: 5732 year: 2013 ident: OOOMB4_2013_v21n6_435_043 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M112.441477 – volume: 131 start-page: 501 year: 2013 ident: OOOMB4_2013_v21n6_435_039 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2012.07.014 – volume: 102 start-page: 6467 year: 2005 ident: OOOMB4_2013_v21n6_435_037 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.0501912102 – volume: 13 start-page: 2276 year: 2012 ident: OOOMB4_2013_v21n6_435_001 publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms13022276 – volume: 6 start-page: 1 year: 2009 ident: OOOMB4_2013_v21n6_435_040 publication-title: J. Infl amm. (Lond) doi: 10.1186/1476-9255-6-1 – volume: 13 start-page: 15 year: 2003 ident: OOOMB4_2013_v21n6_435_002 publication-title: Semin. Cancer Biol. doi: 10.1016/S1044-579X(02)00096-2 – volume: 78 start-page: 943 year: 2012 ident: OOOMB4_2013_v21n6_435_047 publication-title: Planta Med. doi: 10.1055/s-0031-1298626 – volume: 50 start-page: 913 year: 2012 ident: OOOMB4_2013_v21n6_435_030 publication-title: Food Chem. Toxicol. doi: 10.1016/j.fct.2011.11.046 – volume: 64 start-page: 1216 year: 2012 ident: OOOMB4_2013_v21n6_435_048 publication-title: Pharmacol. Rep. doi: 10.1016/S1734-1140(12)70917-9 – volume: 278 start-page: 22237 year: 2003 ident: OOOMB4_2013_v21n6_435_016 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M300847200 – volume: 37 start-page: 790 year: 2010 ident: OOOMB4_2013_v21n6_435_028 publication-title: Clin. Exp. Pharmacol. Physiol. doi: 10.1111/j.1440-1681.2010.05378.x – volume: 26 start-page: 367 year: 2003 ident: OOOMB4_2013_v21n6_435_024 publication-title: Archives of Pharmacal Research doi: 10.1007/BF02976693 – volume: 13 start-page: 85 year: 2001 ident: OOOMB4_2013_v21n6_435_015 publication-title: Cell. Signal. doi: 10.1016/S0898-6568(00)00149-2 – volume: 24 start-page: 4486 year: 2005 ident: OOOMB4_2013_v21n6_435_049 publication-title: Oncogene doi: 10.1038/sj.onc.1208656 – volume: 306 start-page: 805 year: 2003 ident: OOOMB4_2013_v21n6_435_023 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/S0006-291X(03)01073-8 – volume: 99 start-page: 155 year: 1997 ident: OOOMB4_2013_v21n6_435_010 publication-title: J. Allergy Clin. Immunol. doi: 10.1016/S0091-6749(97)70089-7 – volume: 113 start-page: 3547 year: 2012 ident: OOOMB4_2013_v21n6_435_008 publication-title: J. Cell. Biochem. doi: 10.1002/jcb.24232 – volume: 293 start-page: 1495 year: 2001 ident: OOOMB4_2013_v21n6_435_041 publication-title: Science doi: 10.1126/science.1062677 – volume: 91 start-page: 100 year: 2004 ident: OOOMB4_2013_v21n6_435_044 publication-title: J. Cell. Biochem. doi: 10.1002/jcb.10729 – volume: 36 start-page: 1370 year: 2013 ident: OOOMB4_2013_v21n6_435_029 publication-title: Biol. Pharm. Bull. doi: 10.1248/bpb.b13-00146 – volume: 94 start-page: 6358 year: 1997 ident: OOOMB4_2013_v21n6_435_022 publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.94.12.6358 – volume: 18 start-page: 2195 year: 2004 ident: OOOMB4_2013_v21n6_435_018 publication-title: Genes. Dev. doi: 10.1101/gad.1228704 – reference: 11257452 - Cell Signal. 2001 Feb;13(2):85-94 – reference: 14689584 - J Cell Biochem. 2004 Jan 1;91(1):100-17 – reference: 23238477 - Pharmacol Rep. 2012;64(5):1216-22 – reference: 15316034 - J Leukoc Biol. 2004 Nov;76(5):1075-81 – reference: 9177222 - Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6358-63 – reference: 23719635 - Biol Pharm Bull. 2013;36(8):1370-4 – reference: 22408453 - Int J Mol Sci. 2012;13(2):2276-89 – reference: 20925591 - Pharm Biol. 2010 Nov;48(11):1285-90 – reference: 22154852 - Food Chem Toxicol. 2012 Mar;50(3-4):913-9 – reference: 14654230 - Biochim Biophys Acta. 2003 Dec 7;1643(1-3):75-83 – reference: 16490171 - Acta Pharmacol Sin. 2006 Mar;27(3):339-46 – reference: 20718744 - Br J Pharmacol. 2010 Sep;161(1):113-26 – reference: 17700037 - Neuroimmunomodulation. 2007;14(1):24-31 – reference: 15840716 - Proc Natl Acad Sci U S A. 2005 May 3;102(18):6467-72 – reference: 15371334 - Genes Dev. 2004 Sep 15;18(18):2195-224 – reference: 23303186 - J Biol Chem. 2013 Feb 22;288(8):5732-42 – reference: 12711606 - J Biol Chem. 2003 Jun 27;278(26):24233-41 – reference: 15784689 - J Leukoc Biol. 2005 Jun;77(6):975-83 – reference: 18040066 - Exp Biol Med (Maywood). 2007 Dec;232(11):1425-31 – reference: 8071353 - J Biol Chem. 1994 Sep 2;269(35):22269-75 – reference: 8617238 - EMBO J. 1996 Apr 15;15(8):1914-23 – reference: 23685361 - Rheumatology (Oxford). 2013 Sep;52(9):1583-91 – reference: 10228013 - J Immunol. 1999 May 1;162(9):5367-73 – reference: 18483499 - Nat Rev Immunol. 2008 Jun;8(6):478-86 – reference: 19766085 - Immunity. 2009 Sep 18;31(3):425-37 – reference: 23054715 - Arch Pharm Res. 2012 Sep;35(9):1583-9 – reference: 22730200 - J Cell Biochem. 2012 Nov;113(11):3547-58 – reference: 20337656 - Clin Exp Pharmacol Physiol. 2010 Aug;37(8):790-4 – reference: 22137788 - Bioorg Med Chem Lett. 2012 Jan 1;22(1):323-6 – reference: 11520989 - Science. 2001 Aug 24;293(5534):1495-9 – reference: 12785732 - Arch Pharm Res. 2003 May;26(5):367-74 – reference: 21799018 - J Biol Chem. 2011 Sep 23;286(38):32883-9 – reference: 21325641 - Am J Physiol Regul Integr Comp Physiol. 2011 May;300(5):R1152-62 – reference: 9354811 - Physiol Rev. 1997 Oct;77(4):1033-79 – reference: 9042038 - J Allergy Clin Immunol. 1997 Feb;99(2):155-60 – reference: 18494000 - J Cell Biochem. 2008 Sep 1;105(1):70-80 – reference: 21907188 - Biochem Pharmacol. 2011 Dec 1;82(11):1700-8 – reference: 22939756 - J Allergy Clin Immunol. 2013 Feb;131(2):501-11.e1 – reference: 12821113 - Biochem Biophys Res Commun. 2003 Jul 11;306(4):805-11 – reference: 8996240 - J Exp Med. 1997 Jan 6;185(1):43-53 – reference: 15771585 - Annu Rev Immunol. 2005;23:749-86 – reference: 22830990 - J Immunotoxicol. 2013 Apr-Jun;10 (2):133-40 – reference: 22673833 - Planta Med. 2012 Jun;78(10):943-50 – reference: 12637577 - J Biol Chem. 2003 Jun 20;278(25):22237-42 – reference: 15856023 - Oncogene. 2005 Jun 30;24(28):4486-95 – reference: 12507553 - Semin Cancer Biol. 2003 Feb;13(1):15-28 – reference: 19133134 - J Inflamm (Lond). 2009 Jan 08;6:1 – reference: 22484343 - Food Chem Toxicol. 2012 Jul;50(7):2368-75 – reference: 20726986 - Br J Pharmacol. 2010 Dec;161(7):1628-44 |
| SSID | ssj0067156 |
| Score | 2.0913115 |
| Snippet | Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several beneficial pharmacologic effects, which include... Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several beneficial pharmacologic effects, which include... Emodin, a naturally occurring anthraquinone derivative isolated from Polygoni cuspidati radix, has several benefi cial pharmacologic effects, which include... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 435 |
| SubjectTerms | 약학 |
| Title | Emodin Isolated from Polygoni cuspidati Radix Inhibits TNF-α and IL-6 Release by Blockading NF-κB and MAP Kinase Pathways in Mast Cells Stimulated with PMA Plus A23187 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24404333 https://www.proquest.com/docview/1490703935 https://pubmed.ncbi.nlm.nih.gov/PMC3879914 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001822693 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biomolecules & Therapeutics, 2013, 21(6), , pp.435-441 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEF615cIFgXilPDRIHHGwvbbXPqG0atQAqaLSSL2tvA-3Vly7xI5ofhJHrvwIfhMzdhIIKkicbMvjrO1vJ_ONdx6MvVZhEqjMBI7gCEOgY-Okme85oc505mfciDbLdXwSHU-D9-fh-Q5bd0VdvcD6VteO-klN50X_5vPyHSo88tc-miP_LSWqVwXxJQrV4n03infZnXbBiGL5gs2yQiS8tp2rhzYYtTyIuzJEf_uRLVO1W86z21jon8GUv1mn4X12b0UrYdDNgwdsx5YP2dejqwpNE4xwfiGlNEC5JDCpiuUFajLoRX2dU3YDnKYmv4FReZmrvKnh7GTo_PgGaWlg9NGJ4BRNExo7UEs4QNs3a8PugYS-H7RS48EEPuQlyUyQUX5JlzXguOO0buDQFkUNn5r8atHdBH35hcl4AJNiUcMAmV8sHrHp8Ojs8NhZtWZwdMDjxvFNaLXIXGOM77uJ0jpQ1k89ldgkFjxSwsWjOOap9rIkzVwhFPra2qYqNK7V_DHbK6vSPmUghAl56GY2Qu6mPBVzHUShdk2MTM8N3R7z1yhIvapbTu0zCon-C0Enf0EnCTqJ0PXYm81F113Zjn-Lv0J45Uznkspt0_aikrO5RKdiJCkNkZPMGnyJKkjrKmlpq0WN3lNCf5wJD3vsSTcZNoP6VH-Rc95jYmuabARovO0zZX7ZlvnmsUDyHuz_36M8Y3dpt0uXfM72mvnCvkDe1KiXrS78BLe_Gsg |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emodin+Isolated+from+Polygoni+cuspidati+Radix+Inhibits+TNF-%CE%B1+and+IL-6+Release+by+Blockading+NF-%CE%BAB+and+MAP+Kinase+Pathways+in+Mast+Cells+Stimulated+with+PMA+Plus+A23187&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Lu%2C+Yue&rft.au=Jeong%2C+Yong-Tae&rft.au=Li%2C+Xian&rft.au=Kim%2C+Mi+Jin&rft.date=2013-11-01&rft.issn=1976-9148&rft.volume=21&rft.issue=6&rft.spage=435&rft.epage=441&rft_id=info:doi/10.4062%2Fbiomolther.2013.068&rft.externalDBID=n%2Fa&rft.externalDocID=10_4062_biomolther_2013_068 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-9148&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-9148&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-9148&client=summon |